Related Experiment Video
Updated: May 15, 2025

Solid Lipid Nanoparticles SLNs for Intracellular Targeting Applications
Published on: November 17, 2015
Exploring the therapeutic potential of ligand-decorated nanostructured lipid carriers for targeted solid tumor
Zrien Naz1, Mohammad Fareed2, Abdur Rahman Hamidullah Chaudhary3
1Department of Pharmaceutics, College of Pharmacy, Al Asmarya University, Zliten 218521, Libya.
Abstract:
Solid tumors present significant therapeutic challenges due to their complex pathophysiology, including poor vascularization, dense extracellular matrix, multidrug resistance, and immune evasion. Conventional treatment strategies, such as chemotherapy, radiotherapy, and surgical interventions, are often associated with systemic toxicity, suboptimal drug accumulation at the tumor site, and chemoresistance. Nanostructured lipid carriers (NLCs) have emerged as a promising approach to enhance anticancer therapy. NLCs offer several advantages, including high drug loading capacity, improved bioavailability, controlled release, and enhanced stability. Recent advancements in active targeting strategies have led to the development of ligand-decorated NLCs, which exhibit selective tumor targeting, improved cellular uptake, and reduced systemic toxicity. By functionalizing NLCs with different targeting ligands, site-specific drug delivery can be achieved for better therapeutic efficacy. This review comprehensively explores the potential of ligand-decorated NLCs in solid tumor therapy, highlights their design principles, and mechanisms of tumor targeting. Furthermore, it discusses various receptor-targeted NLCs for the effective treatment of solid tumors. The potential of ligand-decorated NLCs in combination therapy, gene therapy, photothermal therapy, and photodynamic therapy is also explored. Overall, ligand-decorated NLCs represent a versatile and effective strategy to achieve better therapeutic outcomes in solid tumor therapy.
Insights
Ligand-decorated nanostructured lipid carriers (NLCs) offer improved delivery for solid tumor therapy. These targeted NLCs enhance drug accumulation and reduce toxicity, improving treatment outcomes.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Solid tumors pose treatment challenges due to resistance and toxicity of conventional therapies.
- Nanostructured lipid carriers (NLCs) show promise for improved drug delivery and stability.
- Active targeting strategies using ligand-decorated NLCs enhance tumor specificity.
Purpose of the Study:
- To review the potential of ligand-decorated NLCs for solid tumor therapy.
- To explore design principles and tumor targeting mechanisms of these nanocarriers.
- To discuss applications in combination, gene, and physical therapies.
Main Methods:
- Review of literature on ligand-decorated NLCs for solid tumor treatment.
- Analysis of NLC design, targeting ligands, and drug delivery mechanisms.
- Exploration of applications in various advanced therapeutic modalities.
Main Results:
- Ligand-decorated NLCs enable selective tumor targeting and improved cellular uptake.
- These nanocarriers reduce systemic toxicity and enhance drug accumulation at the tumor site.
- NLCs show potential in combination therapies, gene therapy, and photothermal/photodynamic therapy.
Conclusions:
- Ligand-decorated NLCs represent a versatile strategy for enhancing solid tumor treatment.
- Targeted delivery via NLCs improves therapeutic efficacy and minimizes side effects.
- Further research into NLCs holds significant promise for overcoming challenges in solid tumor therapy.

